<DOC>
	<DOC>NCT00598793</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). The aim of this trial is to compare biphasic insulin aspart 30 plus metformin in a standard injection regimen to a standard dosing of insulin glargine plus metformin on blood glucose control in subjects with type 2 diabetes who are insulin naive and failing OAD therapy.</brief_summary>
	<brief_title>Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Insulin naive Type 2 diabetes Currently treated with OADs alone or combined with other treatment for at least 3 months BMI below 40 kg/m2 and body weight below 125 kg HbA1c greater than or equal to 8% Inability to tolerate metformin or contradictions to its use Pregnant, breastfeeding or intention of becoming pregnant Allergy to any of the trial products Inability or unwillingness to perform SMBG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>